Boston Standard Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Boston Standard Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Hold	15,165	–	–	0.02%	58
2026 Q1	$96.8K	Buy	+15,165	New	+$126K	0.02%	56
2025 Q4	–	Sell	-15,165	Closed	-$221K	–	53
2025 Q3	$221K	Buy	+15,165	New	+$181K	0.04%	46
2025 Q2	–	Sell	-606,634	Closed	-$203K	–	48
2025 Q1	$203K	Buy	+606,634	New	+$6.18M	0.04%	45
2024 Q4	–	Sell	-15,165	Closed	-$124K	–	48
2024 Q3	$124K	Sell	15,165 -1	-0%	-$10	0.02%	46
2024 Q2	$203K	Hold	15,166	–	–	0.04%	45
2024 Q1	$704K	Hold	15,166	–	–	0.16%	28
2023 Q4	$1.1M	Hold	15,166	–	–	0.29%	25
2023 Q3	$1.1M	Hold	15,166	–	–	0.29%	25
2023 Q2	$1.13M	Hold	15,166	–	–	0.29%	25
2023 Q1	$807K	Hold	15,166	–	–	0.23%	25
2022 Q4	$1.02M	Hold	15,166	–	–	0.3%	22
2022 Q3	$1.89M	Hold	15,166	–	–	0.64%	17
2022 Q2	$1.44M	Buy	+15,166	New	+$1.85M	0.46%	21

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Boston Standard Wealth Management's DNA Position: Q2 2026 in Review

Boston Standard Wealth Management held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 15,165 shares worth $165K. The position accounts for 0.02% of the portfolio, ranked #58.

Boston Standard Wealth Management first reported a position in DNA in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.89M in Q3 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Boston Standard Wealth Management held 15,165 shares of Ginkgo Bioworks worth $165K as of Q2 2026.
Boston Standard Wealth Management left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 0.02% of Boston Standard Wealth Management's portfolio in Q2 2026, its #58 holding.
Boston Standard Wealth Management first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 14 quarters since.
Boston Standard Wealth Management's Ginkgo Bioworks position peaked at $1.89M in Q3 2022.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Boston Standard Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.